LENZ Therapeutics Inc logo

LENZ Therapeutics Inc(LENZ)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$4.13
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for LENZ

11/13/2026: LENZ (1-star) is currently NOT-A-BUY. Pass it for now.

LENZ Therapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and marketing novel ophthalmic solutions for presbyopia. The company's primary strength lies in its flagship candidate VIZZ, which utilizes a pupil-selective miotic mechanism to restore near vision with minimal side effects. Its core growth story centers on capturing market share within a large, underserved global vision care demographic. However, the company faces notable execution, funding, and competition risks from well-established eye care giants. LENZ suits growth-oriented investors willing to accept high volatility, while key developments in prescription adoption and market reimbursement should be closely monitored.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fit while signal remains positiveLENZ offers high-growth exposure centered around the commercial rollout of a novel presbyopia treatment.
Momentum investorMixed fitMomentum fit is conditional on positive technical breakouts and sustained near-term volume uptake.
Value investorWeak fitThe company lacks positive earnings and traditional value metrics due to its early commercial stage.
Dividend investorWeak fitLENZ does not pay dividends and retains all capital for commercial operations.
Low-risk investorWeak fitHigh clinical execution risk and commercialization volatility render the stock unsuitable for conservative profiles.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighBiopharmaceutical stocks frequently experience sharp price swings based on commercial milestones and sentiment.
Valuation riskMedium / highValuations are heavily speculative, depending on long-term revenue projections for VIZZ.
Competition risk (ophthalmic pharma and major eye care giants)HighWell-funded competitors possess massive commercial scale that can challenge market penetration.
Business qualityMediumThe business is anchored by a promising therapeutic asset but lacks multi-product commercial diversification.
Dividend incomeLow / noneNo dividend is offered, providing zero income return for investors.
Execution riskHighSuccessful commercial adoption of VIZZ is paramount for justifying operational expenditure.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 129.77M USD
Price to earnings Ratio -
1Y Target Price 14.83
Price to earnings Ratio -
1Y Target Price 14.83
Volume (30-day avg) 1.1M shares
Beta 1.81
52 Weeks Range 2.80 - 32.13
Updated Date 11/15/2026
52 Weeks Range 2.80 - 32.13
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -4.53

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
45.5%
Active BUY / eligible
20 / 44
30-Day BUY Count Change
+13

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Highly Choppy
PRICE STABILITY

Highly Choppy

The stock has experienced frequent, large price swings that make its near-term movement less predictable.

Analysis of Past Performance

Type Stock
Historic Profit 32.78%
Avg. Invested days 33
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 3.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
LENZ receives a 3-star rating, supported by solid analyst coverage. The rating is constrained by weak unit economics, soft quantitative characteristics, and weak price momentum.

Company Fundamentals

★★★★★
LENZ has moderate overall fundamentals (3 stars), with moderate financial health, soft growth momentum, and solid ownership. In FY2025 versus FY2024, growth and ownership metrics are mixed: negative earnings growth (-65.0%), weak cash generation (FCF margin -366.7%), slightly negative revenue growth (+0.0%).

Financial Health Rating

★★★★★
LENZ's financial health is supported by moderate efficiency, including operating-expense and cost-of-revenue discipline (opex 573.8% of revenue). Cash strength is soft (2 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
LENZ's growth profile is soft, with the least-weak measure being revenue growth at +0.0% FY2025 versus FY2024. By comparison, while earnings growth (-65.0%, negative) and free-cash-flow growth (-16.9%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 91.3% and approximately 70.7% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 2.98% provides only moderate management-shareholder alignment.

Top 5 Institutional Investors

RA Capital Management, LLC 13.30%
Alpha Wave Global LP 11.50%
FMR Inc 11.33%
Versant Venture Management LLC 8.46%
BlackRock Inc 7.30%

Unit Economics (Per $1K Revenue)

★★★★★
LENZ generates approximately $963 of gross profit, $-4,775 of operating income, and $-3,667 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: -0.62% (Tax Credit)

Quantitative Style Profile

★★★★★
LENZ has a liquid profile. Weak momentum is the primary drawback, while soft valuation.

Style Classification

Quality Focused

High VolatilitySmall / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Ophthalmic Pharmaceutical CommercializationSales of prescription eye drop products such as VIZZ intended for vision correction in the United States.The company generates revenue by selling specialized eye drops designed to treat near-vision loss.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Valuation

Trailing PE -
Forward PE -
Enterprise Value -67.08M
Price to Sales(TTM) 10.5
Enterprise Value -67.08M
Price to Sales(TTM) 10.5
Enterprise Value to Revenue 233.94
Enterprise Value to EBITDA -7.99
Shares Outstanding 31.42M
Shares Floating 22.21M
Shares Outstanding 31.42M
Shares Floating 22.21M
Percent Insiders 2.98
Percent Institutions 91.27

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.